Please assess the completion status of the following clinical trial:

Trial Title: Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Volunteers who are healthy 1-4 year old children whose parents/guardians have read the Information Sheet provided by the Principal Investigator and signed the consent form, and who will be available for follow up.~EXCLUSION CRITERIA: Children with~* chronic diseases receiving medication;~* who have received systemic steroids during the month preceding Shigella vaccination;~* who had severe side effects following vaccinations; and~* those not available for follow up.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- S. sonnei conjugate vaccine (Type: EXPERIMENTAL): Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
- S. flexneri 2a conjugate vaccine (Type: EXPERIMENTAL): Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa

Based on this trial design, predict the completion outcome and termination type (if applicable).